Cyclo Therapeutics Inc
NASDAQ:CYTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
US |
|
Moatable Inc
OTC:MTBLY
|
US |
|
Kinnevik AB
STO:KINV B
|
SE |
|
A
|
Alpha Copper Corp
CNSX:ALCU
|
CA |
|
Shanghai Industrial Holdings Ltd
HKEX:363
|
HK |
|
Radient Technologies Inc
XTSX:RTI
|
CA |
|
Physicians Realty Trust
NYSE:DOC
|
US |
|
Borusan Mannesmann Boru Sanayi ve Ticaret AS
IST:BRSAN.E
|
TR |
Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
